Switzerland plans new support for people with rare diseases

More than 500,000 people in Switzerland are estimated to live with a rare disease, according to figures cited by the federal government. On September 2, 2026, the Swiss government announced plans for two laws designed to improve the support available to them.

The first measure would create a legal basis for federal financial support for specialised care structures, information services and advisory organisations. These services can help patients and families navigate complex diagnoses, treatment options and care arrangements across Switzerland’s healthcare system.

The proposal responds to a gap identified years ago. Switzerland adopted a national rare-disease strategy in 2014, and Parliament instructed the government in 2022 to secure a legal framework for financing its measures. The government submitted a bill for consultation last year, including provisions for future support to care networks.

The latest plan separates immediate funding arrangements from the longer-term development of a national register. The government says the approach will allow support structures to move forward while the register is coordinated with the wider digital transformation of healthcare. The proposals still require the normal legislative process before they can take effect.

The first law would put specialised support on a clearer financial footing. The government has not announced a final budget, but it has identified the areas eligible for future federal assistance: specialised care structures, information services and advisory bodies.

Rare diseases often require coordination among hospitals, specialists, primary-care doctors, social services and patient organisations. A small number of patients may be spread across different cantons, while expertise is concentrated in particular clinics. That can make referrals, diagnosis and long-term care difficult to organise.

The planned legal basis could support networks that bring these actors together. It could also strengthen services that explain diagnoses and available care to patients and relatives. The government’s announcement presents the measures as an implementation of the existing national strategy rather than a new policy direction.

For patients, the practical impact will depend on the details of the bill, including eligibility, funding levels and how responsibilities are divided between the Confederation, cantons and existing providers. The federal announcement sets out the intended framework, but it does not yet specify which organisations will receive support or when the first payments could begin. Those decisions will emerge through the legislative process and subsequent implementation.

The national register is planned for 2030 at the earliest, making it the longer-term element of the government’s programme. The Federal Department of Home Affairs has been instructed to prepare a draft bill, but the proposal has not yet been submitted to Parliament.

The government says the register must be developed alongside Digisanté, Switzerland’s programme for the digital transformation of healthcare. Coordination, it argues, would help reuse digital infrastructure, avoid duplicated systems and reduce costs. The consultation on the earlier bill also highlighted the need to align the projects.

A national register could improve the country’s evidence base. Rare diseases are individually uncommon, and information is often distributed among hospitals, laboratories, doctors and patient organisations. A coordinated database could help researchers identify patients, measure needs and study diseases that currently generate limited national data.

The register would also raise practical questions about data quality, consent, privacy and access. The source announcement does not set out those rules. Parliament will need to examine them when the draft legislation arrives. The proposed timetable means the register remains several years away, while the government’s first law is intended to address funding for support structures sooner.

Around 80% of rare diseases are estimated to have a genetic cause, and half manifest in childhood. The government says between 7,000 and 8,000 diseases have been described worldwide. Cystic fibrosis and Pompe disease are among the examples cited in the federal announcement.

Switzerland defines a rare disease as one affecting no more than five people in 10,000 and causing life-threatening or chronically debilitating effects. The definition covers a wide range of conditions, from illnesses that appear in infancy to disorders diagnosed much later in life.

For most rare diseases, no cure currently exists. Treatment and care focus on easing symptoms and improving quality of life. That makes reliable advice, specialist knowledge and continuity of care particularly important for families managing conditions that may be unfamiliar even to healthcare professionals.

The figures also explain why national coordination matters. Each disease may affect a small group, yet the combined number of people living with rare diseases is estimated to exceed half a million in Switzerland. The proposed laws will determine whether the country can translate that broad need into sustained support for patients, relatives, clinicians and researchers.